ProPhase Labs reports FY 2023 net loss of $16.8M; revenue down 63% to $45.2M

ProPhase Labs, Inc.

Net loss of $16.8M ($0.98 per share) vs. net income of $18.5M ($1.17 per share) in FY 2022.
Revenue fell 63% to $45.2M due to COVID-19 testing decline; diagnostic services revenue dropped $83.5M.
Nebula Genomics signed international B2B deal with MenaDNA; potential $10-20M annual revenue from another agreement.
Pharmaloz capacity guidance raised to $45M run-rate by Q3 2024, then $80-100M by H1 2025; existing customers accepted 15.2% price increase.
BE-Smart esophageal cancer test on track for H2 2024 commercialization; Equivir trial interim results showed 68% of respiratory incidents in placebo group.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

ProPhase Labs, Inc. reported financial results for the full-year ended December 31, 2023.

Period: the full-year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 15, 2024, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

ProPhase Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-010013

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.